Jay Bradner, Amgen R&D chief and CSO (Jeff Rumans)

Jay Brad­ner joins Am­gen to lead R&D as David Reese moves to new chief tech­nol­o­gy of­fi­cer role

Am­gen is mak­ing a ma­jor ad­di­tion to its re­search lead­er­ship, bring­ing for­mer No­var­tis re­search ex­ec­u­tive Jay Brad­ner in­to a top role while shift­ing cur­rent R&D chief David Reese to lead tech­nol­o­gy and AI.

Brad­ner left his role last year as head of No­var­tis’ re­search arm, the No­var­tis In­sti­tutes for Bio­Med­ical Re­search, fol­low­ing a ma­jor shake­up at the phar­ma com­pa­ny. He was suc­ceed­ed by Fiona Mar­shall, who was pre­vi­ous­ly Mer­ck’s dis­cov­ery and trans­la­tion­al med­i­cine head. For a year, Brad­ner re­turned to be­ing a clin­i­cian at the Dana-Far­ber Can­cer In­sti­tute and Brigham & Women’s Hos­pi­tal. Be­fore join­ing No­var­tis near­ly eight years ago, Brad­ner had been a well-known physi­cian-sci­en­tist at Dana-Far­ber and Har­vard Med­ical School.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.